Corbus Pharmaceuticals (CRBP) Stock: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$5.38
0.11 (2.09%)
▲
5d:
-12.23%
30d:
-34.71%
90d:
-40.49%
WAIT
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CRBP is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CRBP is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $5.38, which is considered oversold relative to its 30-day fair value range of $6.06 to $9.80.
Technical Outlook: Technically, CRBP is showing sideways momentum. Immediate support is located at $5.13, while resistance sits at $7.18.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $34.02 (+532.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRBP is showing sideways momentum. Immediate support is located at $5.13, while resistance sits at $7.18.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $34.02 (+532.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.06 -
$9.80
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 532.4% below Wall St target ($34.02)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.06 -
$9.80
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.13
Resistance Level
$7.18
Current Trend
Sideways
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.98
Wall Street Target
$34.03
(+532.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 09, 2026 8:15 PM ET
Data refreshes hourly during market hours. Next update: 9:15 PM
Data refreshes hourly during market hours. Next update: 9:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
23 analysts |
$139 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 48 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
16 analysts |
$141 | 63 BUY |
